UroGen Pharma (URGN) Misses Q4 EPS by 15c

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($1.22), $0.15 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $18.09 million versus the consensus estimate of $18.51 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Exclusive: BitGo says institutional conversations are shifting to tokenization
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation